United States: Celltrion Announces Commercial Availability Of ZYMFENTRA™ (Infliximab-dyyb) - Goodwin Procter LLP
Tuesday, 26 March 2024
Celltrion USA announced on March 18, 2024, the availability of ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab.
|
||||
You Might Like |
||||
